Orphazyme's creditors left without real options
The creditors of embattled biotech firm Orphazyme find themselves between a rock and hard place: There’ll be no money left if they reject a proposed restructuring plan, but if they do that, there will be no company to save.
by CHRISTIAN BUNDGAARD, translated by daniel pedersen
Uncertainty continues to surround Orphazyme’s future, even after the proposal of a restructuring plan by the Danish biotech company’s leadership and the restructuring administrator, Gorrissen Federspiel’s John Sommer Schmidt.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme confirms delisting in the US
For subscribers
.jpg&w=384&q=75)
